Mirati Therapeutics
9363 Towne Centre Drive
Suite 200
San Diego
California
92121
United States
Tel: 858-535-2075
311 articles about Mirati Therapeutics
-
Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer
8/23/2023
Mirati Therapeutics, Inc.®, a commercial stage biotechnology company, announced that Laurie Stelzer, Chief Financial Officer, will depart the company on September 8, 2023, to pursue an external opportunity.
-
Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer
8/21/2023
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced a presentation of two-year follow-up from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
-
Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
8/11/2023
Mirati Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 11,288,336 shares of its common stock at a price to the public of $27.80 per share, and, to certain investors, pre-funded warrants to purchase 1,121,736 shares of common stock at a price of $27.799 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant.
-
Mirati Therapeutics Announces Pricing of Upsized Public Offering - August 09, 2023
8/9/2023
Mirati Therapeutics, Inc. announced the pricing of an underwritten public offering of 9,669,631 shares of its common stock at a price to the public of $27.80 per share, and, to certain investors, pre-funded warrants to purchase 1,121,736 shares of common stock at a price of $27.799 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant.
-
Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition
8/9/2023
Mirati Therapeutics, Inc.® announced Cancer Discovery published preclinical and initial clinical data from a first-in-human Phase 1/2 clinical trial of MRTX1719, a PRMT5 / methylthioadenosine -cooperative inhibitor evaluated in methylthioadenosine phosphorylase deleted cancers.
-
Following an FDA approval and a Phase III flop, Mirati CEO David Meek has resigned in a “mutually agreed” decision, the company announced late Tuesday as it searches for a permanent replacement.
-
Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
8/8/2023
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the second quarter 2023 along with recent pipeline and corporate updates.
-
Mirati Therapeutics Announces Proposed Public Offering - August 08, 2023
8/8/2023
Mirati Therapeutics, Inc., a commercial stage biotechnology company, announced that it intends to offer and sell $250.0 million of shares of its common stock, and, to certain investors, pre-funded warrants to purchase shares of common stock, in an underwritten public offering.
-
Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek
8/8/2023
Mirati Therapeutics, Inc.®, a commercial stage biotechnology company announced that David Meek and the Company mutually agreed for Mr. Meek to step down from his role as CEO and as a member of the Board of Directors.
-
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - August 03, 2023
8/3/2023
Mirati Therapeutics, Inc.® announced that the company granted equity awards to a new employee with a grant date of August 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan and material to the employee's acceptance of employment with the company.
-
Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023
7/25/2023
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the second quarter 2023 along with recent corporate updates on August 8, 2023.
-
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
7/21/2023
Mirati Therapeutics, Inc. today announced the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Conditional Marketing Authorisation Application (MAA) for KRAZATI ®.
-
Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
6/23/2023
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher.
-
Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases
6/20/2023
Mirati Therapeutics, Inc.® (NASDAQ: MRTX) announced today the Journal of Clinical Oncology published clinical results from the KRYSTAL-1 study of adagrasib, a potent and selective KRASG12C inhibitor, demonstrating durable IC activity in patients living with KRASG12C-mutated NSCLC with untreated CNS metastases.
-
Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023
6/1/2023
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 on June 15 at 8:40 a.m. P.T. / 11:40 a.m. E.T.
-
Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting
5/30/2023
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced presentations and posters to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating the utility of adagrasib across multiple tumor types.
-
The investigational kinase inhibitor failed to improve overall survival in the SAPPHIRE study of patients with non-squamous non-small cell lung cancer, causing Mirati to discontinue its development.
-
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®
5/24/2023
Mirati Therapeutics, Inc.®, a commercial-stage oncology company, announced that the SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis.
-
Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates
5/9/2023
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates.
-
Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies
5/8/2023
Mirati Therapeutics, Inc.® and Sarah Cannon Research Institute announced a strategic partnership aimed at increasing diversity in clinical study recruitment practices.